Primary colon cancer with a high serum PIVKA-II level

Liebman, 1984, Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma, N. Engl. J. Med., 310, 1427, 10.1056/NEJM198405313102204 Kudo, 1992, Des-gamma-carboxy prothrombin (PIVKA-II) and alpha-fetoprotein-producing IIc-type early gastric cancer, Am. J. Gastroenterol., 87, 1859 Hasegawa, 2005, Des-g-carboxy Prothrombin (PIVKA II)-producing mediastinal embryonal carcinoma with features of hepatoid differentiation, Anticancer Res., 25, 4569 Stenflo, 1977, Vitamin K-dependent formation of gamma-carboxyglutamic acid, Annu. Rev. Biochem., 46, 157, 10.1146/annurev.bi.46.070177.001105 Tsai, 1990, Plasma des-gamma-carboxyprothrombin in the early stage of hepatocellular carcinoma, Hepatology, 11, 481, 10.1002/hep.1840110321 Ishii, 2000, Stimulus measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellualar carcinoma, South Tohoku District Study Group, Am. J. Gastroenterol., 95, 1036 Koike, 2001, Protein induced by vitamin K absence or antagonist-II as useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma. A prospective analysis of 227 patients, Cancer, 91, 561, 10.1002/1097-0142(20010201)91:3<561::AID-CNCR1035>3.0.CO;2-N Suehiro, 1994, Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma, Comparison with alpha-fetoprotein, Cancer, 73, 2464, 10.1002/1097-0142(19940515)73:10<2464::AID-CNCR2820731004>3.0.CO;2-9 Fujikawa, 2007, Des-gamma-carboxy prothrombin-promoted vascular endothelial cell proliferation and migration, J. Biol. Chem., 282, 8741, 10.1074/jbc.M609358200 Huisse, 1994, Mechanism of the abnormal vitamin K-dependent gamma-carboxylation process in human hepatocellular carcinomas, Cancer, 74, 1533, 10.1002/1097-0142(19940901)74:5<1533::AID-CNCR2820740507>3.0.CO;2-V Takahashi, 2010, Protein induced by vitamin K absence or antagonist II-producing gastric cancer, World J. Gastrointest Pathophysiol., 15, 129, 10.4291/wjgp.v1.i4.129 Sinard, 1994, Hepatoid adenocarcinoma in the urinary bladder: Unusual localization of a newly recognized tumor type, Cancer, 73, 1919, 10.1002/1097-0142(19940401)73:7<1919::AID-CNCR2820730724>3.0.CO;2-L Kato, 1996, Colon cancer with a high serum alpha-fetoprotein level, Am. J. Gastroenterol., 91, 1045 Tang, 2003, Des-r-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma, Int. J. Oncol., 22, 969 Nagai, 1993, Hepatoid adenocarcinoma of the stomach: a clinicopathologic and immunohistochemical analysis, Cancer, 72, 1827, 10.1002/1097-0142(19930915)72:6<1827::AID-CNCR2820720606>3.0.CO;2-8 Takano, 2004, PIVKA-II-producing advanced gastric cancer, Int. J. Clin. Oncol., 9, 330, 10.1007/s10147-004-0398-0 Bast, 2001, 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology, J. Clin. Oncol., 19, 1865, 10.1200/JCO.2001.19.6.1865 Koprowski, 1979, Colorectal carcinoma antigens detected by hybridoma antibodies, Somatic Cell Genet., 5, 957, 10.1007/BF01542654 Mclntire, 1975, Serum α-fetoprotein in patients with neoplasms of the gastrointestinal tract, Cancer Res., 35, 991 Allegretta, 2011, Therapeutic potential of targeting glypiacn-3 hepatocelluar carcinoma, Anticancer agents Med. Chem., 11, 543, 10.2174/187152011796011109